Related Experiment Videos

Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes

Marco Cippitelli1, Cinzia Fionda, Danilo Di Bona

  • 1Department of Experimental Medicine and Pathology, Istituto Pasteur-Fondazione Cenci Bolognetti, University La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy. marco.cippitelli@uniroma1.it

Insights

Vitamin D (1,25(OH)(2)D(3)) inhibits Fas Ligand (FasL) gene activation in T cells, reducing cell death and offering potential autoimmune disease treatments. This study reveals FasL as a new target for Vitamin D

Area of Science:

  • Immunology
  • Molecular Biology
  • Endocrinology

Background:

  • Fas/FasL system regulates T cell apoptosis, crucial for immune homeostasis and tolerance.
  • Dysregulated Fas/FasL is implicated in autoimmune diseases.
  • 1,25(OH)(2)D(3) (active Vitamin D) has known immunosuppressive effects.

Purpose of the Study:

  • To investigate the effect of 1,25(OH)(2)D(3) on Fas Ligand (FasL) gene activation in T lymphocytes.
  • To elucidate the molecular mechanisms by which 1,25(OH)(2)D(3) regulates FasL expression.

Main Methods:

  • Assessed 1,25(OH)(2)D(3) impact on activation-induced cell death and FasL mRNA expression in T cells.
  • Analyzed FasL promoter activity using VDR (Vitamin D Receptor) reporter assays.
  • Identified key promoter regions and transcription factor binding sites involved in repression.

Main Results:

  • 1,25(OH)(2)D(3) significantly inhibits activation-induced cell death and FasL mRNA expression.
  • VDR activation by 1,25(OH)(2)D(3) represses FasL promoter activity.
  • Repression mechanism requires VDR DNA-binding and AF-2 domains, involving a c-Myc-binding element in the promoter.

Conclusions:

  • FasL is a novel molecular target for the immunoregulatory actions of 1,25(OH)(2)D(3).
  • These findings support the potential therapeutic use of 1,25(OH)(2)D(3) and its analogs in autoimmune conditions.

Related Concept Videos